Literature DB >> 20664766

The MYH7 p.R787H mutation causes hypertrophic cardiomyopathy in two unrelated families.

G Purushotham1, K Madhumohan, Mohammad Anwaruddin, Ha Nagarajaram, Vuppaladadhiam Hariram, Calambur Narasimhan, Murali D Bashyam.   

Abstract

BACKGROUND: Familial hypertrophic cardiomyopathy (FHC) is a Mendelian disorder usually caused by mutations in any one of more than 12 genes, most of which encode sarcomere proteins. The disease exhibits extensive genetic heterogeneity, and it is important to identify mutations that result in adverse symptoms and/or lethality in affected individuals. An analysis of disease-causing mutations has been initiated in the Indian population to determine prevalent mutations.
METHODS: FHC was detected using echocardiography and by analysis of clinical symptoms and family history. The disease-causing mutation was identified using polymerase chain reaction DNA sequencing.
RESULTS: The p.R787H mutation was identified in the MYH7 gene in two FHC families. Sequence and structure analysis suggested impaired binding of the mutant protein to the myosin essential light chain.
CONCLUSIONS: Although the mutation results in variable clinical symptoms in the affected individuals, probably owing to the effect of modifier genes and/or environmental factors, it does not appear to be a lethal mutation.

Entities:  

Keywords:  Beta-cardiac myosin heavy chain 7 gene; Familial hypertrophic cardiomyopathy; Hypertrophy; Mutation

Year:  2010        PMID: 20664766      PMCID: PMC2907879     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  20 in total

1.  Expression of HCM causing mutations: lessons learnt from genotype-phenotype studies of the South African founder MYH7 A797T mutation.

Authors:  J Moolman-Smook; W De Lange; V Corfield; P Brink
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

2.  A structural state of the myosin V motor without bound nucleotide.

Authors:  Pierre-Damien Coureux; Amber L Wells; Julie Ménétrey; Christopher M Yengo; Carl A Morris; H Lee Sweeney; Anne Houdusse
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

3.  Three myosin V structures delineate essential features of chemo-mechanical transduction.

Authors:  Pierre-Damien Coureux; H Lee Sweeney; Anne Houdusse
Journal:  EMBO J       Date:  2004-10-28       Impact factor: 11.598

Review 4.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

5.  Hypertrophic cardiomyopathy: an introduction to pathology and pathogenesis.

Authors:  M J Davies; W J McKenna
Journal:  Br Heart J       Date:  1994-12

6.  Cardiac myosin heavy chains lacking the light chain binding domain cause hypertrophic cardiomyopathy in mice.

Authors:  R E Welikson; S H Buck; J R Patel; R L Moss; K L Vikstrom; S M Factor; S Miyata; H D Weinberger; L A Leinwand
Journal:  Am J Physiol       Date:  1999-06

7.  Prevalence of cardiac beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy.

Authors:  Andreas Perrot; Hajo Schmidt-Traub; Bernard Hoffmann; Matthias Prager; Nana Bit-Avragim; Raisa I Rudenko; Dinara A Usupbaeva; Zhyldyz Kabaeva; Bakytbek Imanov; Mirsaid M Mirrakhimov; Rainer Dietz; Anna Wycisk; Michal Tendera; Reinhard Gessner; Karl Josef Osterziel
Journal:  J Mol Med (Berl)       Date:  2005-04-22       Impact factor: 4.599

Review 8.  Molecular genetics of familial hypertrophic cardiomyopathy (FHC).

Authors:  Murali D Bashyam; Gorinabele R Savithri; Murugapiran S Kumar; Calambur Narasimhan; Pratibha Nallari
Journal:  J Hum Genet       Date:  2003       Impact factor: 3.172

9.  A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease.

Authors:  K Lindpaintner; M A Pfeffer; R Kreutz; M J Stampfer; F Grodstein; F LaMotte; J Buring; C H Hennekens
Journal:  N Engl J Med       Date:  1995-03-16       Impact factor: 91.245

10.  Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy.

Authors:  I Rayment; H M Holden; J R Sellers; L Fananapazir; N D Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

View more
  4 in total

1.  A low prevalence of MYH7/MYBPC3 mutations among familial hypertrophic cardiomyopathy patients in India.

Authors:  Murali D Bashyam; Guroji Purushotham; Ajay K Chaudhary; Katika Madhumohan Rao; Vishal Acharya; Tabrez A Mohammad; Hampapathalu A Nagarajaram; Vuppaladadhiam Hariram; Calambur Narasimhan
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

2.  Succinate causes pathological cardiomyocyte hypertrophy through GPR91 activation.

Authors:  Carla J Aguiar; João A Rocha-Franco; Pedro A Sousa; Anderson K Santos; Marina Ladeira; Cibele Rocha-Resende; Luiz O Ladeira; Rodrigo R Resende; Fernando A Botoni; Marcos Barrouin Melo; Cristiano X Lima; José M Carballido; Thiago M Cunha; Gustavo B Menezes; Silvia Guatimosim; M Fatima Leite
Journal:  Cell Commun Signal       Date:  2014-12-24       Impact factor: 5.712

3.  The novel mitochondrial 16S rRNA 2336T>C mutation is associated with hypertrophic cardiomyopathy.

Authors:  Zhong Liu; Yanrui Song; Dan Li; Xiangyu He; Shishi Li; Bifeng Wu; Wei Wang; Shulian Gu; Xiaoyu Zhu; Xuexiang Wang; Qiyin Zhou; Yu Dai; Qingfeng Yan
Journal:  J Med Genet       Date:  2013-12-23       Impact factor: 6.318

4.  Phenotypic diversity identified by cardiac magnetic resonance in a large hypertrophic cardiomyopathy family with a single MYH7 mutation.

Authors:  Jie Wang; Ke Wan; Jiayu Sun; Weihao Li; Hong Liu; Yuchi Han; Yucheng Chen
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.